Dutch startup Meatable has acquired the cultivated meat platform of UK-based Uncommon Bio, which is pivoting its focus to the therapeutics industry. The acquisition gives Meatable key technology, intellectual property assets, and cell lines that allow it to diversify its product line and accelerate development of new cultivated meat products. Notably, Uncommon Bio’s technology uses a non-genetically modified organism (non-GMO) approach to differentiate stem cells into fat and muscle, which Meatable says will help them achieve faster regulatory approval and speed up their entry into new markets and species like chicken and lamb.
Source: Meatable acquires Uncommon Bio’s cultivated meat platform as latter pivots to therapeutics